Chand Subhash, Jo Ala, Vellichirammal Neetha Nanoth, Gowen Austin, Guda Chittibabu, Schaal Victoria, Odegaard Katherine, Lee Hakho, Pendyala Gurudutt, Yelamanchili Sowmya V
Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Center for Systems Biology, Massachusetts General Hospital, Boston, MA, 02114, USA.
ACS Appl Nano Mater. 2020 Sep 25;3(9):8906-8919. doi: 10.1021/acsanm.0c01654. Epub 2020 Aug 6.
Extracellular vesicles (EV) are nano-sized vesicles that have been garnering a lot of attention for their valuable role as potential diagnostic markers and therapeutic vehicles for a plethora of pathologies. Whilst EV markers from biofluids such as plasma, serum, urine, cerebrospinal fluid and cell culture based platforms have been extensively studied, a significant knowledge gap that remains is the characterization of specific organ derived EVs (ODE). Here, we present a standardized protocol for isolation and characterization of purified EV isolated from brain, heart, lung, kidney and liver from rat and postmortem human tissue. Next, using quantitative mass spectrometry based proteomics, we characterized the respective tissue EV proteomes that identified synaptophysin (SYP), caveolin-3 (CAV3), solute carrier family 22 member 2 (SLC22A2), surfactant protein B (SP-B), and fatty acid-binding protein 1 (FABP1) as potential markers for the brain, heart, kidney, lung, and liver-EV, respectively. These respective tissue specific markers were further validated using both immunoblotting and a nanoplasmonic platform- single EV imaging analysis in the two species. To summarize, our study for the first time using traditional biochemical and high precision technology platforms provide a valuable proof of concept approach in defining specific ODE markers which further could be developed as potential therapeutic candidates for respective end-organ associated pathologies.
细胞外囊泡(EV)是纳米级囊泡,因其作为多种病理状态下潜在诊断标志物和治疗载体的重要作用而备受关注。虽然来自血浆、血清、尿液、脑脊液等生物流体以及基于细胞培养平台的EV标志物已得到广泛研究,但仍存在一个重大知识空白,即特定器官来源的EV(ODE)的表征。在此,我们提出了一种标准化方案,用于从大鼠和死后人体组织的脑、心脏、肺、肾和肝脏中分离和表征纯化的EV。接下来,我们使用基于定量质谱的蛋白质组学方法,对各个组织的EV蛋白质组进行了表征,确定突触素(SYP)、小窝蛋白-3(CAV3)、溶质载体家族22成员2(SLC22A2)、表面活性蛋白B(SP-B)和脂肪酸结合蛋白1(FABP1)分别作为脑、心脏、肾脏、肺和肝脏-EV的潜在标志物。这些各自组织特异性标志物在两个物种中均通过免疫印迹和纳米等离子体平台——单EV成像分析进一步得到验证。总之,我们的研究首次使用传统生化和高精度技术平台,为定义特定ODE标志物提供了一种有价值的概念验证方法,这些标志物进一步可开发为各自终末器官相关病理状态的潜在治疗候选物。